摘要
Abstract
AIM To investigate the clinical efficacy and safety of flunarizine hydrochloride capsules combined with betaustine hydrochloride on Meniere's disease(MD).METHODS A total of 98 patients diagnosed with Meniere's disease from December 2021 to December 2023 were selected and randomly divided into control group and trial group,with 49 patients in each group.The control group was treated with betahistine hydrochloride,while the trial group was treated with flunarizine hydrochloride capsules combined with betamethasone hydrochloride.Both groups were treated continuously for 21 days.The clinical efficacy,improvement of dizziness symptoms,hemorheological indicators(erythrocyte aggregation index,whole blood viscosity,and hematocrit),dizziness handicap inventory(DHI)scores,mean hearing threshold,degree of tinnitus,and adverse reactions of 2 groups were observed after treatment.RESULTS After 21 days of treatment,the total effective rate of the trial group was 91.84％,which was higher than the control group's 71.43％(P＜0.05).The disappearance time of dizziness,seizure frequency,seizure duration,and DHI scores decreased after treatment,with the trial group showing significantly lower values than the control group(P＜0.05).The erythrocyte aggregation index,whole blood viscosity,hematocrit,mean hearing threshold,and tinnitus improved post-treatment,and these measures were significantly better in the trial group compared to the control group(P＜0.05).CONCLUSION Flunarizine hydrochloride capsule combined with betaustine hydrochloride can improve clinical symptoms and hemorheological indices in Meniere's disease(MD)patients,enhance hearing,and exhibits a better therapeutic effect than betahistine alone.Furthermore,the combination regimen demonstrates good safety and is worthy of clinical recommendation.关键词
梅尼埃病/氟桂利嗪/倍他司汀/眩晕/血液流变学Key words
Meniere's disease/flunarizine hydrochloride capsule/betahistine hydrochloride/hemorheology/dizziness
